

C12Q 1/68

C12Q 1/68(0063)

(C12Q 1/68(0063)) ✓

AID

2231392

PROPERTY ORGANIZATION
Bureau

1494

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 5 :	A1	(11) International Publication Number: WO 93/01313
C12Q 1/68, G01N 33/535		(43) International Publication Date: 21 January 1993 (21.01.93)

(21) International Application Number: PCT/GB92/01229	(74) Agent: KEITH W. NASH & CO.; Pearl Assurance House, 90-92 Regent Street, Cambridge CB2 1DP (GB).
(22) International Filing Date: 6 July 1992 (06.07.92)	
(30) Priority data: 9114525.0 5 July 1991 (05.07.91) GB	(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).
(71) Applicant (for all designated States except US): CYTOCELL LIMITED [GB/GB]; Home Farm, Hill Road, Lewknor, Oxfordshire OX9 5TS (GB).	
(72) Inventors; and	Published
(75) Inventors/Applicants (for US only) : CARDY, Donald, Leonard, Nicholas [GB/GB]; "Trinlan", Blacksmith's Lane, Aston-le-Walls, Northamptonshire NN11 6UF (GB). DELNATTE, Sabine, Yolande, Joseph [BE/GB]; Home Farm, Hill Road, Lewknor, Oxfordshire OX9 5TS (GB).	With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NUCLEIC ACIDS ASSAY

(57) Abstract

Disclosed is a homogeneous assay method for determining the presence of a nucleic acid sequence of interest in a sample, comprising combining in solution: the sample; a first nucleic acid probe substantially complementary or homologous to at least part of the sequence of interest and associated, or capable of being associated, with an enzyme or a substance capable of affecting the activity of an enzyme; a second probe capable of binding to the first probe or capable of binding to at least part of the sequence of interest and comprising a ligand moiety; and a binding partner capable of binding to said ligand moiety, the arrangement being such that when the first and second probes are bound in proximity an effect of the binding partner on enzyme behaviour is altered; and monitoring said enzyme behaviour.



- 1 -

TITLE: NUCLEIC ACIDS ASSAY

The present invention relates to methods for homogeneous nucleic acid probe-based tests for genetic materials whereby the formation of a nucleic acids hybrid modulates a signal-producing moiety or intermediate resulting in production of or a change in the signal. In particular, the present invention relates to methods whereby the formation of a nucleic acids hybrid modulates the activity of an enzyme or an enzyme intermediate. The present invention also relates to substances required for such homogeneous nucleic acids-based tests.

In the current state-of-the-art, laboratory nucleic acid probe-based assays for detection of genetic material, for example from living organisms, usually require the purification of genetic material from these organisms followed by its immobilisation on a solid phase, typically a nitrocellulose membrane. The membrane is then usually incubated with a DNA probe labelled with either a radioactive moiety (for example, phosphorous-32), an enzyme (for example, alkaline phosphatase) or any other signal producing moiety or intermediate. The membrane is then washed to remove non-hybridised DNA probe before undertaking the appropriate steps for analysis of signal associated with the membrane (for example autoradiography for phosphorous-32, addition of an enzyme substrate for alkaline phosphatase). For detailed protocols for such assays, reference may be made to Molecular Cloning, A Laboratory Manual, (eds. Sambrook, Fritsch and Maniatis, Cold Spring Harbor 1989). Such laboratory probe-based assays can be termed "heterogeneous DNA probe assays" whereby, following hybridisation, the hybridised DNA probe must be separated from the unhybridised DNA probe in

- 2 -

the solution phase in order to determine the presence of specific genetic material as measured by signal associated with the membrane

Such heterogeneous nucleic acid probe-based assays require a number of different manipulation steps including extensive washing of the solid phase in order to remove excess probe. The large number of steps makes automation or routine use difficult such that heterogeneous assays have not been widely introduced for analyses (for example, in routine clinical testing).

Nucleic acid probe-based assays where no separation of hybridised and unhybridised DNA probe is required for signal generation can be termed "homogeneous DNA probe assays". The main principle of such assays is that hybridised probe gives rise to a different signal from unhybridised probe such that separation of hybridised and unhybridised probe is unnecessary. Thus, simply by measuring the development of the modified signal resultant from hybridisation can the presence of genetic material be determined. Such homogeneous assays therefore avoid any need for separation or washing steps such that suitable preparations of genetic material can be simply mixed with one or more reagents in succession to produce the final modified signal. Such separation steps are a major cause of variability in assay results, are time and labour consuming, require additional equipment and make automation more difficult and expensive. Prospectively, homogeneous nucleic acid probe assays will be simple enough for routine clinical testing and other routine applications and will readily lend themselves to automation using, for example, existing high-throughput clinical analysers in cases where analysers are capable of measuring the final modified signal.

- 3 -

from the homogeneous assay. There is currently an unsatisfied need for simple homogeneous nucleic acids probe-based assays.

Several methods for homogeneous DNA probe assays have been described in the patent or scientific literature. Invariably, these fall within two categories, either assays where the signal derives from the interaction of a molecule on one probe with that on another probe, or assays where the process of hybridisation affects or creates one or more signal producing moieties attached to the DNA probe. Thus EP144914 assigned to Miles describes the interaction of a molecule on one DNA probe with a molecule on an adjacently hybridising DNA probe whereby the molecules interact through enzyme channelling or fluorescence energy transfer to produce a signal. EP232967 assigned to Amoco provides a competitive assay variation of EP144914 whereby the two DNA probes normally hybridise together to produce a signal but where a test nucleic acid competes for hybridisation with one probe to produce a different signal (fluorescence in the example provided). EP229943 assigned to Molecular Biosystems appears to be a more specific variation of EP144914 comprising fluorescence energy transfer between adjacently hybridised probes.

Patents whereby hybridisation affects or creates signalling are exemplified by EP144913 assigned to Miles whereby species recognised by an antibody are created by hybridisation of a nucleic acid probe to its target. EP231495 assigned to Enzo appears to broaden this concept to produce a "property change" upon hybridisation which is the signal. One example given is the alteration in fluorescence of a dye conjugated to a DNA probe which intercalates into hybrids formed to give a modified fluorescence signal. A

- 4 -

novel hybridisation associated "change" is described by Vary (Nucl. Acids Res. 15 (1987) p6883) whereby the hybridisation of target DNA to a DNA probe already hybridised to a RNA strand is possible through the displacement of the RNA strand to produce a single-stranded RNA species. Such a single-stranded RNA species is then susceptible to hydrolysis by polynucleotide phosphorylase with the release of ADP. Subsequently, ADP can be converted to ATP for estimation by luciferase-catalysed chemiluminescence.

Whilst each of the above described homogeneous nucleic acid probe methodologies are conceptually elegant, none has yet proved suitable for commercialisation. The major difficulties include non-specific hybridisation associated signalling changes and the general limitations, where applicable, of fluorescence measurements particularly at wavelengths which are finely restricted to exclude other fluorescences and where background and variability are problems. The only homogeneous DNA probe assay to achieve a level of commercial success is disclosed in EP309230 assigned to ML Technology Ventures. This has been successfully adapted by Genprobe Corporation whereby fluorescent acridinium ester moieties attached to a DNA probe are selectively degraded in unhybridised probe but protected in hybrids formed by the acridinium-labelled probe. Whilst this fluorescence assay has been successfully adapted for detection of the abundant ribosomal RNA from microorganisms such as C. trachomatis and N. gonorrhoeae, the sensitivity of the assay will limit many other DNA probe applications especially for analysis of single copy mammalian genes. From the precedent of antibody-based assays (i.e. immunoassays), the key to higher sensitivities is an assay involving an enzyme-generated signal where

- 5 -

the enzyme product can either be allowed to accumulate to give extra sensitivity or can itself be used as a substrate or cofactor for another enzyme activity.

The concept of homogeneous assays is well known in the field of immunoassays (i.e. assays involving antibodies) whereby the binding of one or more antibodies to a specific analyte results in development or modification of a signal producing moiety. Nevertheless, few homogeneous immunoassay systems have proved commercially viable and none readily lend themselves to nucleic acid probe-based assays. The enzyme-labelled systems commercialised by the Syva company (Rubenstein et al, US Patent No 3817837, Rubenstein and Ullman, US Patent No 3875011) involve the binding of a low molecular weight analyte to an enzyme whereby an antibody which binds to the analyte modulates the signal produced by the enzyme. These and related Syva patents (for example US 3817837, US3852157, US3875011, US3905871, US3966556, US4039385, US4040907, US4043872, US4046636, US4065354, US4067774, US4171244 and US 4191613) do not teach how to apply such processes to nucleic acid hybridisation assays nor is such application obvious. The substrate-labelled systems commercialised by the Ames company (Burd et al, Clin. Chem. 23 (1977) p1402 and Anal. Biochem. 77 (1977) p56) involve the production of a non-fluorescent analyte conjugate whose hydrolysis to yield a fluorescent moiety can be blocked by an analyte specific antibody. This system is also limited to low molecular weight analytes and does not obviously apply to nucleic acids hybridisations. The fluorescence polarisation system commercialised by the Abbott company (Dandliker et al, Immunochemistry 10 (1973) p219) is similar in concept to the Ames system except the analyte is conjugated to a fluorescent

- 6 -

molecule whose fluorescence is modified directly as a change in polarisation through binding of an antibody specific for the analyte. The enzyme inhibitor system of Kallestad (Bacquet and Twumasi, Anal. Biochem. 136 (1984) p487) involves the inhibition of biotin-dependant enzymes by analyte-conjugated avidin and reversal of this inhibition by an antibody specific for the analyte. Both the Abbott and Kallestad systems suffer from low sensitivity (analyte concentrations usually $>10^{-10}$ M), by application limited to low molecular weight analytes (usually <1000 daltons), and by no obvious application to nucleic acid hybridisation assays.

One successful homogeneous immunoassay system which has improved sensitivity and has application to large molecular weight analytes has been commercialised by the Microgenics company (Henderson, EP 199801 and PCT 86/02666). This is based on a feature of relatively few enzymes whose activity can be reconstituted by the recombination of inactive fragments of enzyme. In this assay system, the analyte is attached to a peptide fragment from beta-galactosidase which can activate enzyme activity when mixed with the remaining beta-galactosidase protein. Analyte-specific antibody can interfere with this recombination to preclude enzyme activity whilst added analyte will compete for antibody binding to the peptide-analyte fragment to allow enzyme activation in an analyte concentration-dependant fashion. This assay system is not restricted to low molecular weight analytes and has a sensitivity $>10^{-10}$ M). However from EP199801 and related patents, it is not obvious how to apply this assay system for nucleic acid hybridisations. Indeed, the claims refer to an analyte binding protein which directly competes with the beta-galactosidase

- 7 -

"enzyme-acceptor" (i.e. the inactive partial beta-galactosidase protein) with the peptide-analyte conjugate. Neither the claims nor the patent description indicate how the process of nucleic acid hybridisation could interfere with activation of enzyme activity by the beta-galactosidase peptide.

Despite the precedents from the immunoassay field, no enzyme-based homogeneous nucleic acid hybridisation-based assays are known in the literature and thus there is a great need for such assays. Thus, the present invention comprises methods for homogeneous nucleic acid probe-based hybridisation assays based on modulation of enzyme activity. The key finding in relation to the invention is that nucleic acid probes can either be attached to a moiety which activates an enzyme or directly to the enzyme itself without respectively abolishing the enzyme activation or the enzyme activity, and which in principle can be attached to a moiety which inhibits an enzyme without abolishing inhibition of enzyme activity. The invention then provides the means for modulating enzyme activity through the hybridisation of derivatised nucleic acid probes whereby moieties attached to the probe either directly or indirectly interfere respectively with enzyme activity, activation or inhibition.

One embodiment of the current invention provides a means to modulate the reconstitution of an active enzyme by nucleic acid hybridisation. A key finding in the development of this "homogeneous DNA probe-based enzyme activation assay" is that nucleic acids can, by certain methods, be attached to an inactive peptide component of an enzyme without precluding the ability of that peptide to activate enzyme activity. Another key

finding is that hybridisation of unmodified nucleic acids alone to this nucleic acid-peptide conjugate is not sufficient to totally preclude enzyme activation (although larger nucleic acid molecules can reduce activation). Thus, unlike in the immunoassay system described in EP199801, the "analyte" (nucleic acid)-peptide conjugate in a nucleic acid probe-based assay cannot be directly inhibited from reconstituting enzyme activity by hybridisation with a complementary sample-derived nucleic acid analyte molecule. In the immunoassay system of EP199801, the analyte-peptide conjugate is inhibited from reconstituting enzyme activity by an "analyte-binding protein", invariably an antibody, which binds to the analyte both in the analyte-peptide conjugate or as free analyte. When free analyte is introduced as in a test sample, then a proportion of the antibody is diverted to binding to free analyte leaving a proportion of the analyte-peptide conjugate free to reconstitute enzyme activity. For this system to be applied directly to nucleic acids, an analyte-binding protein would be needed which recognises a nucleic acid-peptide conjugate together with the free nucleic acid. It is well understood that development of an antibody (or any other protein) with high specificity for a specific nucleic acid sequence is very difficult and thus alternative non-obvious ways would be needed to apply the system of EP199801 to nucleic acids. During the development of the present invention, it was considered possible that a synthetic nucleic acid molecule with a nucleotide sequence complementary to that of the nucleic acid-peptide conjugate might inhibit reconstitution of enzyme activity; it was also considered that, in turn, this inhibition might be reversed by the introduction of a free nucleic acid from a test sample with the same or a similar sequence as the synthetic nucleic acid molecule which would divert the synthetic nucleic acid molecule away from the nucleic acid-peptide

- 9 -

conjugate. Thus, it was envisaged that the synthetic nucleic acid molecule would act in an analogous manner to the analyte-binding protein in EP199801 by inhibiting reconstitution of enzyme activity until sequestered by a test sample analyte. However, it was discovered that a synthetic complementary nucleic acid molecule, as with a complementary sample nucleic acid molecule, failed to efficiently inhibit the reconstitution of enzyme activity. Instead, it was discovered that the synthetic nucleic acid molecule with a nucleotide sequence complementary to that of the nucleic acid-peptide conjugate could be modified by certain methods to effectively inhibit reconstitution of enzyme activity. A preferred method is to locate a ligand molecule on the synthetic nucleic acid which is subsequently bound by an antibody which inhibits reconstitution, possibly by steric hindrance. Unlike in the immunoassay example, the antibody in the case of nucleic acids hybridisation does not bind directly to the analyte-peptide conjugate. An alternative method is to use an antibody or nucleic acid binding protein (or any other molecule) specific for single-stranded nucleic acid which will bind to the nucleic acid-peptide conjugate and inhibit reconstitution of enzyme activity. The hybridisation of a complementary test nucleic acid to the nucleic acid-peptide conjugate can then preclude antibody or protein binding thus allowing enzyme reconstitution. Unlike in the immunoassay example, the antibody (or binding moiety) in the case of nucleic acids hybridisation is not diverted from the analyte-peptide conjugate by binding to analyte from the sample but rather by the nucleic acid in the conjugate becoming double-stranded. An alternative method still is to employ a modified synthetic nucleic acid-peptide conjugate whereby an antibody binds to the specific modification and inhibits reconstitution of enzyme activity but whereby the

- 10 -

hybridisation of a complementary test nucleic acid to the nucleic acid-peptide conjugate can then preclude antibody or protein binding thus allowing enzyme reconstitution. An alternative method still is to employ a modified synthetic nucleic acid molecule which, instead of hybridising directly to the nucleic acid-peptide conjugate, will hybridise adjacent to the nucleic acid-peptide conjugate on a contiguous strand of target nucleic acid whereby, as in the preferred method, an antibody can bind to a ligand on the modified nucleic acid molecule and inhibit enzyme reconstitution by the nucleic acid-peptide molecule.

A further embodiment of the current invention provides a means to directly modulate enzyme activity by nucleic acid hybridisation. A key finding during development of this "homogeneous DNA probe-based direct enzyme inhibition assay" is that nucleic acids can, by certain methods, be conjugated to an active enzyme without total inhibition of enzyme activity. Another key finding is that hybridisation of unmodified nucleic acids alone to this nucleic acid-enzyme conjugate is not sufficient to modulate enzyme activity unlike in the equivalent immunoassays (for example, US 3875011) where the direct binding of an antibody to the conjugate will modulate enzyme activity. Instead, it has been recognised that the hybridising nucleic acid in this case must be modified by certain methods in order to modulate (e.g. inhibit) enzyme activity. A preferred method is to locate a ligand molecule on the hybridising nucleic acid which is subsequently bound by an antibody leading to inhibition of enzyme activity. Unlike in the immunoassay examples, the antibody in the case of nucleic acid hybridisation does not bind directly to the analyte-enzyme conjugate.

- 11 -

A further embodiment of the current invention provides a means for indirectly modulating enzyme-inhibition by nucleic acid hybridisation. It is likely that nucleic acids can, by certain methods, be conjugated to an enzyme-inhibiting moiety (such as avidin) without appreciably reducing the inhibition of enzyme activity. It is likely that hybridisation of unmodified nucleic acids alone to this nucleic acid-protein conjugate is not sufficient to reduce inhibition of enzyme activity unlike in the equivalent immunoassay (for example, Bacquet and Twumasi, loc. cit.) where the direct binding of an antibody to the conjugate will prevent the inhibition of enzyme activity. Instead, it is likely that the hybridising nucleic acid in this case must be modified by certain methods in order to reverse inhibition of enzyme activity. A preferred method is to locate a ligand molecule on the hybridising nucleic acid which is subsequently bound by an antibody which may thus prevent access of the inhibiting moiety to the inhibiting site on the enzyme. Unlike in the immunoassay examples, the antibody in the case of nucleic acid hybridisation does not bind directly to the analyte-protein conjugate.

A further embodiment of the current invention relates to the modulation of an enzyme activity (by activation, inhibition or blocking of an inhibitor) whereby hybridisation of two nucleic acids probes effects the formation of a binding moiety through the juxtaposition of two components conjugated to the probes. A preferred binding moiety is an antibody variable region binding site whereby the heavy and light chain variable region fragments of an antibody molecule could be attached respectively to the 5' and 3' ends of complementary DNA probes which, on hybridisation, juxtaposes the two variable region fragments to produce an antigen binding species. This

- 12 -

antigen binding species could, for example, bind directly to an enzyme to inhibit the enzyme activity, bind to an activating moiety of an enzyme or bind to an inhibiting moiety of an enzyme.

It will be apparent to those skilled in the art that the process of nucleic acids hybridisation with at least one modified nucleic acids probe could be used in many different ways to create a molecular species which can either directly or indirectly modulate an enzyme activity.

Specific embodiments of the invention will now be described by way of example with reference to the accompanying drawings in which:-

Figures 1 to 3, 12 and 13, and 14 and 15 illustrate homogeneous DNA probe-based enzyme activation assays whereby the signal is produced by activation of an enzyme;

Figures 4 to 6 illustrate a homogeneous DNA probe-based direct enzyme inhibition assay whereby the signal is produced by inhibition of an enzyme;

Figures 7 to 9 illustrate a homogeneous DNA probe-based indirect enzyme inhibition assay whereby the signal is produced by interference with the inhibition of an enzyme;

Figures 10 and 11 illustrate a homogeneous DNA probe-based assay whereby the signal results from the hybridisation-induced formation of a binding protein.

- 13 -

Figure 16 shows the amino acid sequence of the synthetic "cysteine/peptide" of beta-galactosidase as used for examples 1 and 2 below.

Figures 17 and 18 show the effect of sample human CFTR gene "PCR fragment" on the enzyme activation assays described in examples I.IV and I.VI respectively.

Referring to figure 1, one version of the enzyme activation assay comprises an inactive enzyme fragment 1 which can be activated by a peptide conjugated to a nucleic acid probe 2 to restore enzyme activity.

Referring to figure 2, by hybridisation of a second nucleic acid probe 3 to which is attached a ligand which then becomes associated a ligand-specific antibody 4, the activation of enzyme fragment 1 by the peptide conjugated nucleic acid probe 2 is inhibited. Referring to figure 3, by competition for hybridisation to ligand associated probe 3 by the test nucleic acids 5, the extent of hybridisation of probe 3 to probe 2 is thus reduced to leave a proportion of probe 2 unhybridised and thus able to activate enzyme fragment 1.

Referring to figure 12, another version of the enzyme activation assay comprises the same inactive enzyme fragment 1 as in figures 1 to 3 which can be activated by a peptide conjugated to a nucleic acid probe 2 to restore enzyme activity. In this case, a single-stranded nucleic acid specific antibody 20 (or other sequence-specific or non-specific molecule with appropriate binding specificity) is included which binds to the peptide conjugated nucleic acid 2 to inhibit enzyme activation. As in figure 13, the specific antibody 20 (or other molecule) are conversely

unable to bind to peptide conjugated nucleic acid 2 when this becomes hybridised with target nucleic acid 5 and thus the peptide conjugated nucleic acid is free for activation of enzyme fragment 1.

Referring to figure 14, another version of the enzyme activation assay comprises the same inactive enzyme fragment 1 as in figures 1 to 3 which can be activated by a peptide conjugated to a nucleic acid probe 2 to restore enzyme activity. In this case, a second nucleic acid probe 21 is included which is non-complementary to the peptide-nucleic acid 2 and to which is attached a ligand which then becomes associated a ligand-specific antibody 4. However, as illustrated in figure 15, the activation of enzyme is only inhibited when the nucleic acid-peptide molecule 2 and the ligand-derivatised nucleic acid 21 hybridise adjacently to a target nucleic acid 5 whereby the binding of ligand-specific antibody 4 interferes with activation of the enzyme fragment 1 by the nucleic acid-peptide 2.

It will be understood to those skilled in the art that as alternatives to beta-galactosidase, other enzymes could be used where it is possible to split off a peptide with a loss of enzyme activity which is then automatically restored upon interaction of the peptide with the inactive enzyme fragment. For example, N-terminal peptide fragments of RNAase S can be removed and added back to restore full enzyme activity.

Referring to figures 4, the enzyme inhibition assay comprises an enzyme 6 to which a nucleic acid probe is attached. Referring to figure 5, the probe is attached in 6 such that hybridisation by a second nucleic acid probe 7 to which is attached a ligand and subsequent binding to this probe

- 15 -

by a ligand-specific antibody 8 results in inhibition of the enzyme activity. Referring to figure 6, by competition for hybridisation to probe 7 by test nucleic acid 9, the hybridisation of probe 7 to the enzyme-bound probe 6 is inhibited leaving the enzyme-bound probe free of ligand-specific antibody 8 and thus active.

It will be understood by those skilled in the art that the present discovery that nucleic acid probes in combination with certain other molecules such as antibodies can directly inhibit the activity of enzymes such as G6PD may also apply to a range of other enzymes, for example beta-galactosidase. This inhibition may be mediated, for example, by attachment of a nucleic acid molecule near to the active site of the enzyme whereby on hybridisation of a complementary ligand-associated probe and the subsequent attachment of anti-ligand antibody, the enzyme activity is inhibited. This inhibition may then be reversed by the competition of target genetic material for the ligand-associated probe which cannot then hybridise near to the active site of the enzyme.

Referring to figure 7, an avidin-conjugated nucleic acid probe 10 inhibits a biotin-dependant enzyme 11 (for example, pyruvate decarboxylase) through interaction with the biotin cofactor for the enzyme. Referring to figure 8, this inhibition may be reversed by the hybridisation of a complementary nucleic acid probe 12 to which is attached a ligand group which, in turn, becomes bound by a ligand-specific antibody 13. The indirect attachment of the antibody to the avidin molecule interferes with the access of the avidin molecule to the enzyme thus reversing the inhibition by avidin.

Referring to figure 9, the hybridisation of a target nucleic acid 14 in

- 16 -

competition with the probe 12 to the avidin-associated probe 10 circumvents the subsequent binding by antibody 13 allowing free interaction of avidin to the pyruvate decarboxylase molecule. It will be understood by those skilled in the art that alternative moieties which indirectly modulate the activity of an enzyme might be substituted for avidin in the example herein. As an alternative to avidin, the enzyme inhibiting moiety might, for example, be an antibody which binds to an allosteric site or a region near the enzyme active-site thus modulating enzyme activity.

Referring to figure 10, a nucleic acid probe associated antibody heavy-chain variable (VH) region 15 can become associated, by hybridisation, with a complementary probe associated light-chain variable (VL) region 16 to produce an antigen combining site through the combination of antibody heavy and light-chains. If the antigen combining site binds to an enzyme activating peptide 17, then the activation of an inactive enzyme fragment 18 can be reduced. Referring to figure 11, by competition with, for example, probe 15 by a target nucleic acid 19 for hybridisation to probe 16, the combination of variable regions can be eliminated thus allowing the enzyme activating peptide 17 to activate enzyme fragment 18.

It will be understood by those skilled in the art that other molecules or parts of molecules may be induced to interact through coattachment of these molecules to 2 nucleic acids probes which hybridise to each other. The combination of these 2 molecules might, for example, produce a protein which binds to a third molecule. In the example herein, the 2 molecules comprise the variable regions of an antibody molecule, one with a heavy chain variable region and the other with a light chain variable region, the

- 17 -

combination of these which binds to a peptide activator of an enzyme. The hybridisation of the nucleic acid probes thus forms an antibody variable region which binds to the peptide thus inhibiting activation of the enzyme. This inhibition can be reversed by competition of the target genetic material for one or both of the nucleic acid probes. The formation of an antibody variable region might also be used to directly modulate an enzyme activity by binding at or near the active site, by binding to a cofactor of the enzyme or by binding to another molecule which modulates enzyme activity. The homogeneous nucleic acid probe-based assays described herein circumvent many of the difficulties in achieving practical hybridisation assays particularly through avoidance of a solid phase. Assays may be undertaken by mixing together dilutions of target genetic material with nucleic acid probe, enzyme and antibody reagents and by recording enzyme activities at specific timepoints. Alternatively, samples and reagents may be loaded into an appropriate commercially available clinical analyser and the dilution, mixing and optical density measurements could then be undertaken by the machine.

The invention can be further understood from the following more detailed descriptions which are given by way of example and should not be regarded as limiting the scope of the invention.

- 18 -

Example 1 - HOMOGENEOUS ENZYME ACTIVATION ASSAYS FOR CFTR GENES

In this example, the enzyme activation assays as referred to in figures 1 to 3 and 12 to 15 were adapted for the detection of CFTR (Cystic Fibrosis related) genes in human DNA. The peptide-nucleic acid probe conjugates 2 of the figures will be hereafter called the "activator oligonucleotides" whilst the ligand-associated nucleic acid probes 3 of the figures will be hereafter referred to as the "blocker oligonucleotides". The enzyme system used was beta-galactosidase whereby the alpha peptide complements the M15 mutant of this enzyme (Ullmann et al, J. Mol. Biol., 24 (1967) p339) to restore beta-galactosidase activity.

I. Preparation of Activator Oligonucleotide

The activator oligonucleotide probes included the following nucleotide sequences:

CFTR (A) - 5'-AATATCATTTGGTGTTC-3'

CFA508 (A) - 5'-GAAAATATCATCGGTGTTC-3'

All oligonucleotides were synthesised on an Applied Biosystems 380A synthesiser with nucleoside phosphoramidites. CFTR (A) and CFA508 (A) were each synthesised with a primary 3'-aliphatic amine by synthesis on a 3'-amino-ON CPG support supplied by Cruachem (UK) and using manufacturer's instructions. All oligonucleotides were purified by reverse-phase HPLC on a Unimetrics 5u RP-8 column using a linear-gradient of 7-35% acetonitrile in 100mM sodium acetate. 100ug each of CFTR (A) and CFA508 (A) were 5'-end

- 19 -

labelled with trace amounts of ^{32}P using 0.1uCi $^{32}\text{PATP}$ (Amersham, 3000Ci/mmol) and 100 units of T4 polynucleotide kinase (Boehringer) in 200ul using conditions recommended with the enzyme. The labelled oligonucleotides were then heated to 80°C for 10 minutes, extracted twice with buffer equilibrated phenol (Gibco BRL) and chloroform (1:1), extracted once with chloroform, made 0.3M in sodium acetate pH5.2 and precipitated with 2 volumes of ice-cold ethanol. The pellets were washed once in 70% ethanol and lyophilised.

Two alternative forms of beta-galactosidase peptide were used, one comprising a 43 residue fragment with an N-terminal cysteine, herein called the cysteine/peptide, with an amino acid sequence detailed in figure 16 and the other comprising a plasmid derived alpha-peptide with an N-terminal methionine, herein called the methionine/peptide, as isolated from bacterial cells as detailed below. The cysteine/peptide was synthesised on an Applied Biosystems 431A peptide synthesiser using manufacturer's reagents and protocols and the peptide was purified using an Applied Biosystems ABS151A Separation System. The peptide was then dialysed into 1mM ammonium bicarbonate/1mM mercaptoethanol and lyophilised. The methionine/peptide was isolated from E.coli TG1 cells (obtained from Dr George Salmond, Dept Biological Sciences, University of Warwick, Coventry, UK) harbouring the plasmid pUC8 (obtained from CP Laboratories, Southampton, UK). Cells were grown in M9 medium (Molecular Cloning, supra) containing 100ug/ml ampicillin (sodium salt, Sigma, Poole, UK) and 0.02% w/v glucose. At A_{600nm} = 0.4, IPTG (isopropyl thiogalactopyranoside, Sigma) was added to 1mM final concentration, cells were grown to A₆₀₀ = 0.9, cells were pelleted and resuspended in 10ml of buffer A (0.05M

- 22 -

12.5% Swank Munkres SDS-polyacrylamide gel (Anal. Biochem., 99 (1979) p170) using trace 5'-32P labelling of oligonucleotide (Molecular Cloning, supra) in order to identify the conjugate band which was then excised, eluted into buffer A and dialysed in buffer A.

II. Preparation of Blocker Oligonucleotides

The blocker oligonucleotides comprised the following oligonucleotide sequences complementary to the corresponding activator oligonucleotides (CFTR (B) and CFA508 (B)) and to a site on the CFTR gene adjacent to that complementary to the activator oligonucleotides (CFTR(C));

CFTR (B) - 5'-GAAACACCAAAGATGATATT-3'

CFA508 (B) - 5'-GAAACACCGATGATATTTTC-3'

CFTR (C) - 5'-CTATGATGAATATAGATACA-3'

These oligonucleotides were synthesised with a 5'-bromodeoxyuridine nucleoside by incorporation of a 5-bromodeoxyuridine cyanoethyl phosphoramidite (Cruachem) into the synthesis.

III. Preparation of Target DNA

DNA samples were obtained from a normal individual homozygous for the non-mutated CFTR (cystic fibrosis transregulator) gene and from an individual afflicted with cystic fibrosis by virtue of a homozygous deletion of codon 508 in the CFTR gene. DNA was derived from buccal cells obtained from these individuals by gentle scraping of the buccal lining with a sterile

- 23 -

toothpick. Buccal cells were then suspended in 10ul sterile water, lysed with 20ul 0.1M potassium hydroxide and 0.1% Triton-X-100 at 65°C for 20 minutes, and neutralised with 20ul of 0.1M HCl and 0.1% Triton-X-100.

Regions of the CFTR gene were then amplified by the polymerase chain reaction (PCR) procedure as described in EP200362 (Cetus Corp). 5ul of the human cell lysate was denatured at 94°C for 3 minutes and mixed into 5ul of 20mM Tris.HCl pH8.3, 100mM potassium chloride, 3mM magnesium chloride, 20ng/ml bovine serum albumin (fraction V, Sigma), 400uM deoxyribonucleotide mixture (Pharmacia), 0.1% Triton-X-100, 0.05 units *Thermus aquaticus* DNA polymerase (Perkin Elmer) and 0.5uM oligonucleotide amplification primers (5'-CAGTGGAAAGAATGGCATTCTGTT-3' and 5'-GGCATGCCTTGATGACGCCCTCTG-3'). Amplification was undertaken by 40 cycles in a thermal cycler (Techne, model PHC-2) comprising successive steps of 93°C for 1 minute, 55°C for 1.5 minutes and 72°C for 3 minutes. An additional 0.05 units of polymerase was added at the 20 cycle stage.

IV. Hybridisation Analysis with Anti-Activator Antibody

Hybridisations analyses were undertaken as illustrated in figures 12 and 13. Hybridisation reactions comprised mixtures of DNA derived from normal individuals (confirmed homozygous wild-type CFTR gene), prepared as described in III. above, with the oligonucleotide combination CFTR(A) and CFTR(B). In addition, controls comprised mixtures without human DNA. For hybridisation, 10 pmoles of methionine peptide/oligonucleotide conjugate was mixed with dilutions of target human DNA (or PCR buffer blank) in 50ul of 5% formamide, 0.6M sodium chloride and 0.06M sodium citrate at pH7 and

- 24 -

mixtures were incubated at 37°C for 30 minutes. 50ul of a 1:5 dilution in 0.15M NaCl and 0.015M sodium citrate pH7 of anti-single stranded DNA antibody (clone number 1619, Biogenesis, Bournemouth, UK) was added and the incubation continued for a further 30 minutes.

Beta-galactosidase activity was measured as follows. To the above mixture was added 900ul of a mixture comprising 1mg/ml ONPG, 125 pmoles of M15 preparation in 1mM magnesium sulphate, 0.18mM manganese sulphate, 1mM ethylene diamine tetraacetic acid and 0.5M sodium phosphate buffer, pH7. The mixture was incubated for 30 minutes at 37°C and the optical absorbance at 420nm was measured. The results are shown in figure 17 and show that the introduction of human DNA results in an increased beta-galactosidase activity than in the control.

V. Hybridisation Analysis with Complementary Blocker Oligonucleotide

Hybridisation analyses were undertaken as illustrated in figures 2 and 3. Hybridisation reactions comprised mixtures of DNA, prepared as described in III. above, derived from normal or cystic fibrosis afflicted individuals either with the oligonucleotide combination CFTR(A) and CFTR(B) or the combination CFA508(A) and CFA508(B). In addition, controls comprised mixtures without human DNA. For hybridisation, 10 pmoles of cysteine peptide/oligonucleotide conjugate was mixed with 20 pmoles of blocker oligonucleotide and 2ul of human DNA (or PCR buffer blank) in 50ul of 5% formamide, 0.6M sodium chloride and 0.06M sodium citrate at pH7 and mixtures were incubated at 37°C for 30 minutes. 20ul of an anti-

bromodeoxyuridine antibody (Amersham) diluted 1:2 in 10ul 0.6M sodium chloride was added and the incubation continued for a further 30 minutes.

Beta-galactosidase activity was measured as follows. To the above mixture was added 440ul of a mixture comprising 1mg/ml ONPG, 125 pmoles of M15 preparation in 1mM magnesium sulphate, 0.18mM manganese sulphate, 1mM ethylene diamine tetraacetic acid and 0.5M sodium phosphate buffer, pH7. The mixture was incubated for 30 minutes at 37°C and the optical absorbance at 414nm was measured. The results are expressed as percentage beta-galactosidase (beta-gal) activity of that with the CFTR(A) activator in the absence of blocker oligonucleotide and were as follows;

<u>Activator/Blocker</u>	<u>Human DNA</u>	<u>% Beta-Gal Activity</u>
CFTR(A) /none	none	100 (A414=1.16)
CFA508(A)/none	none	89
CFTR(A) /CFTR(B)	none	8
CFA508(A)/CFA508(B)	none	4
CFTR(A) /CFTR(B)	normal	66
CFTR(A) /CFTR(B)	cystic fibrosis	28
CFA508(A)/CFA508(B)	normal	33
CFA508(A)/CFA508(B)	cystic fibrosis	74

- 26 -

These results demonstrate discrimination of normal and cystic fibrosis DNA through a simple homogeneous beta-galactosidase activation assay.

VI. Hybridisation Analysis with Adjacent Blocker Oligonucleotide

Hybridisation analyses were undertaken as illustrated in figures 14 and 15. Hybridisation reactions comprised mixtures of normal human DNA (confirmed homozygous CFTR gene) prepared as described in III. above with the oligonucleotide combination CFTR(A) and CFTR(C). In addition, controls comprised mixtures without human DNA. For hybridisation, 10 pmoles of cysteine peptide/oligonucleotide conjugate CFTR(A) was mixed with 10 pmoles of blocker oligonucleotide CFTR(C) and dilutions of human DNA (or PCR buffer blank) in 50ul of 5% formamide, 0.6M sodium chloride and 0.06M sodium citrate at pH7 and mixtures were incubated at 37°C for 30 minutes. 20ul of an anti-bromodeoxyuridine antibody (Amersham) diluted 1:2 in 10ul 0.6M sodium chloride was added and the incubation continued for a further 30 minutes.

Beta-galactosidase activity was measured as described in V. above and the results, as shown in figure 18, show that the introduction of human DNA results in a dose dependant decrease in beta-galactosidase activity.

- 27 -

Example 2 - HOMOGENEOUS ENZYME ACTIVATION ASSAY FOR p53 GENES

In this example, the enzyme activation assays as referred to in figures 1 to 3 and as described in example 1 was applied for the detection of the human p53 anti-oncogene.

I. Preparation of Activator Oligonucleotide

The activator oligonucleotide probes included the following nucleotide sequences:

p53 (A) - 5'-GGCATGAACCGGAGGCC-3'

p53mut (A) - 5'-GGCATGAACCAGAGGCC-3'

Oligonucleotides were synthesised and conjugated to cysteine/peptide as in example 1 above.

II. Preparation of Blocker Oligonucleotides

The blocker oligonucleotides comprised the following oligonucleotide sequences complementary to the corresponding activator oligonucleotides;

p53 (B) - 5'-GGGCCTCCGGTTCATGCC-3'

p53 mut (B) - 5'-GGGCCTCTGGTTCATGCC-3'

These oligonucleotides were synthesised with a 5'-bromodeoxyuridine nucleotide as in example 1.

- 28 -

III. Preparation of Target DNA

DNA samples were obtained from the human lymphoma cell line RAJI (ATCC7936) which is homozygous for a tract of p53 sequence complementary to p53(A) and (B) as above. 10^4 cells were suspended in 100ul sterile water, lysed with 200ul 0.1M potassium hydroxide and 0.1% Triton-X-100 at 65°C for 20 minutes, and neutralised with 200ul of 0.1M HCl and 0.1% Triton-X-100.

Regions of the p53 gene were then amplified by the polymerase chain reaction (PCR) procedure as described in example 1. 5ul of the human cell lysate was denatured at 94°C for 3 minutes and mixed into 5ul of 20mM Tris.HCl pH8.3, 100mM potassium chloride, 3mM magnesium chloride, 20ng/ml bovine serum albumin (fraction V, Sigma), 400uM deoxyribonucleotide mixture (Pharmacia), 0.1% Triton-X-100, 0.05 units *Thermus aquaticus* DNA polymerase (Perkin Elmer) and 0.5uM oligonucleotide amplification primers (5'-ATGCGAATTCCCTGCCCTCAACAAAGAT-3' and 5'-TATAGGAATTCTGGTGAGGCTCCCTT-3'). Amplification was undertaken by 35 cycles in a thermal cycler (Techne, model PHC-2) comprising successive steps of 94°C for 1 minute, 55°C for 2 minutes and 72°C for 3 minutes.

IV. Hybridisation Analysis with Complementary Blocker Oligonucleotide

Hybridisation analyses were undertaken as illustrated in figures 2 and 3. Hybridisation reactions comprised mixtures of DNA, prepared as described in III. above, either with the oligonucleotide combination p53(A) and p53(B), the combination p53mut(A) and p53mut(B) or activator oligonucleotides alone. In addition, controls comprised mixtures without human DNA. For

- 29 -

hybridisation, 10 pmoles of cysteine peptide/oligonucleotide conjugate was mixed with 20 pmoles of blocker oligonucleotide and 2ul of human DNA (or PCR buffer blank). Hybridisation conditions, addition of anti-bromodeoxyuridine antibody and measurement of beta-galactosidase activity was as in example 1 above. The results were as follows;

<u>Activator/Blocker</u>	<u>Human DNA</u>	<u>A414nm (Beta-Gal Activity)</u>
p53(A) /p53(B)	2ul	0.96
p53(A) /p53(B)	none	0.16
p53(A)	2ul	1.23
p53(A)	none	1.33
p53mut(A)/p53mut(B)	2ul	0.38
p53mut(A)/p53mut(B)	none	0.18
p53mut(A)	2ul	0.94
p53mut(A)	none	1.17

These results demonstrate the detection of the normal p53 anti-oncogene (combination of p53(A) and (B) oligonucleotides) through a simple homogeneous beta-galactosidase activation assay.

Example 3 - HOMOGENEOUS ENZYME INHIBITION ASSAY FOR CFTR GENES

In this example, the enzyme inhibition assay as referred to in figures 4 to 6 was adapted for the detection of Cystic Fibrosis genes in human DNA. The

- 32 -

<u>Activator/Blocker</u>	<u>Human DNA</u>	<u>% G6PDH Activity</u>
CFTR(A) /none	none	100 (A350=0.113/minute)
CFA508(A)/none	none	95
CFTR(A) /CFTR(B)	none	35
CFA508(A)/CFA508(B)	none	34
CFTR(A) /CFTR(B)	normal	57
CFTR(A) /CFTR(B)	cystic fibrosis	26
CFA508(A)/CFA508(B)	normal	36
CFA508(A)/CFA508(B)	cystic fibrosis	64

These results demonstrate discrimination of normal and cystic fibrosis DNA through a simple homogeneous G6PDH enzyme inhibition assay.

- 33 -

It will be apparent from the foregoing to those skilled in the art that a large number of different assay formats are envisaged within the scope of the present invention.

These include assays in which the sequence of interest competes with one probe for binding to the other probe and assays in which the sequence of interest is capable of binding to both probes.

The assay method of the present invention requires a detectable change in the behaviour of an enzyme. Such changes may include the generation of enzyme activity, an increase or a decrease in enzyme activity.

Thus probes may be joined to enzymes, enzyme fragments, enzyme inhibitors, enzyme activators or enzyme co-factors.

The sequence of interest may be a synthetic nucleic acid, a nucleic acid obtained from a prokaryotic or eukaryotic cell or derived by polymerase chain reaction. Typically, its size will be in the range from 10-10,000 nucleotides long.

Similarly, the probes may be synthetic oligonucleotides or derived from substantially natural sources. They may comprise synthetic base analogues, such as bromodeoxyuridine, which act as the ligand for a binding partner (such as anti-bromodeoxyuridine antibodies).

CLAIMS

1. A homogeneous assay method for determining the presence of a nucleic acid sequence of interest in a sample, comprising combining in solution: the sample; a first nucleic acid probe substantially complementary or homologous to at least part of the sequence of interest and associated, or capable of being associated, with an enzyme or a substance capable of affecting the activity of an enzyme; a second probe capable of binding to the first probe or capable of binding to at least part of the sequence of interest and comprising a ligand moiety; and a binding partner capable of binding to said ligand moiety, the arrangement being such that when the first and second probes are bound in proximity an effect of the binding partner on enzyme behaviour is altered; and monitoring said enzyme behaviour.
2. A method according to claim 1, wherein the second probe is a nucleic acid.
3. A method according to claim 2, wherein the first probe is substantially homologous to the sequence of interest and the second probe is substantially complementary to the sequence of interest.
4. A method according to claim 2, wherein the first and second probes are both substantially complementary to the sequence of interest and are both capable of binding to the sequence of interest in close proximity.
5. A method according to claim 1, wherein the second probe performs the function of the binding partner in the assay.

- 35 -

6. A method according to claim 5, wherein the first probe is substantially complementary to the sequence of interest and the second probe is an antibody directed against the first probe.

7. A method according to claim 6, wherein the first probe comprises a synthetic base analogue and the second probe is an antibody directed against said synthetic base analogue.

8. A method according to claim 7, wherein said synthetic base analogue comprises bromodeoxyuridine.

9. A method according to claim 2, wherein the first and second probes comprise two respective parts of a binding site which is formed when the first and second probes come into close proximity.

10. A method according to claim 9, wherein the first probe comprises an antibody V_H or V_L domain and the second probe comprises a complementary antibody V_L or V_H domain, respectively.

11. A method according to any one of claims 1 to 9, wherein the first probe is associated with an enzyme, enzyme fragment, enzyme inhibitor, enzyme activator or enzyme co-factor.

12. A method according to claim 11, wherein the first probe is associated with a fragment of beta-galactosidase or RNase S.

13. A method according to claim 12, wherein the first

- 36 -

probe is associated with the M15 mutant fragment of beta-galactosidase.

14. A method according to claim 12, wherein the first probe is associated with a fragment of beta-galactosidase comprising the amino acid sequence shown in Figure 16, or functional equivalents thereof.

15. A method according to claim 1, wherein the first probe is capable of being associated with a biotin-dependent enzyme.

16. A method according to claim 1, wherein the first probe is associated with avidin.

17. A method according to claim 15 or 16, wherein the first probe is capable of associating with pyruvate decarboxylase.

18. A method according to claim 11, wherein the first probe is associated with glucose-6-phosphate dehydrogenase.

19. A method according to any one of the preceding claims, wherein the sequence of interest comprises any nucleic acid greater than 10 nucleotides long.

20. A method according to claim 19, wherein the sequence of interest comprises any nucleic acid less than 10,000 nucleotides long.

21. A method according to any one of the preceding claims wherein the enzyme behaviour is monitored quantitatively.

- 37 -

22. A homogeneous assay method for determining the presence of a nucleic acid sequence of interest in a sample, comprising combining in solution: the sample; a first nucleic acid probe substantially complementary or homologous to at least part of the sequence of interest; and an enzyme or part thereof, the arrangement being such that the behaviour of the enzyme is affected in a detectable way by the presence or absence of the sequence of interest; and monitoring said enzyme behaviour.

23. A composition comprising a nucleic acid conjugated to an enzyme, enzyme fragment, enzyme inhibitor, enzyme activator or enzyme co-factor.

24. A composition comprising a nucleic acid conjugated to one part of a binding pair whereby the addition of the other part of the binding pair results in the formation of a binding moiety.

25. A composition according to claim 24, wherein the two parts of the binding pair comprise an antibody V_H domain and an antibody V_L domain.

26. A kit for performing the method of claim 1, comprising a first nucleic acid probe, a second probe, an enzyme substrate and a binding partner.









**Fig 2.****Fig 3.**

Fig 4.**Fig 5.****Fig 6.**

3/9

Fig 7.




Fig 8.




Fig 9.




Fig 10.




Fig 11.




Figure 12




Figure 13




Figure 14






Figure 15



SUBSTITUTE SHEET


8/9

Figure 17



9/9

Figure 18



SUBSTITUTE SHEET

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. GB 9201229
SA 62810

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 17/11/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0149339	24-07-85	AU-B-	569076	21-01-88
		AU-A-	2775384	08-11-84
		AU-B-	583258	27-04-89
		AU-A-	3832985	26-06-85
		CA-A-	1220818	21-04-87
		CA-A-	1223639	30-06-87
		EP-A-	0125139	14-11-84
		WO-A-	8502627	20-06-85
		JP-T-	61500706	17-04-86
		US-A-	4840893	20-06-89
EP-A-0144913	19-06-85	US-A-	4743535	10-05-88
		AU-B-	578436	27-10-88
		AU-A-	3656084	20-06-85
		AU-B-	578641	03-11-88
		AU-A-	3656184	20-06-85
		AU-B-	579335	24-11-88
		AU-A-	3656284	20-06-85
		AU-B-	580745	02-02-89
		AU-A-	3656384	20-06-85
		CA-A-	1250230	21-02-89
		CA-A-	1239580	26-07-88
		CA-A-	1250232	21-02-89
		CA-A-	1238575	28-06-88
		EP-A-	0146039	26-06-85
		EP-A-	0144914	19-06-85
		EP-A,B	0146815	03-07-85
		JP-A-	60151559	09-08-85
		JP-A-	60201256	11-10-85
		JP-A-	60201257	11-10-85
		JP-A-	60179657	13-09-85
		US-A-	4563417	07-01-86
EP-A-0144914	19-06-85	AU-B-	578436	27-10-88
		AU-A-	3656084	20-06-85
		AU-B-	578641	03-11-88
		AU-A-	3656184	20-06-85
		AU-B-	579335	24-11-88
		AU-A-	3656284	20-06-85
		AU-B-	580745	02-02-89

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. GB 9201229
SA 62810

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 17/11/92

Page 2

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0144914		AU-A- 3656384 CA-A- 1250230 CA-A- 1239580 CA-A- 1250232 CA-A- 1238575 EP-A- 0144913 EP-A- 0146039 EP-A, B 0146815 JP-A- 60151559 JP-A- 60201256 JP-A- 60201257 JP-A- 60179657 US-A- 4563417	20-06-85 21-02-89 26-07-88 21-02-89 28-06-88 19-06-85 26-06-85 03-07-85 09-08-85 11-10-85 11-10-85 13-09-85 07-01-86
EP-A-0232967	19-08-87	JP-A- 62244399	24-10-87
WO-A-8602666	09-05-86	US-A- 4708929 US-A- 5120653 AU-B- 592324 AU-A- 5068385 EP-A- 0199801 JP-T- 62500633	24-11-87 09-06-92 11-01-90 15-05-86 05-11-86 19-03-87
EP-A-0309230	29-03-89	AU-A- 2554188 JP-T- 2503147 WO-A- 8902476	17-04-89 04-10-90 23-03-89
EP-A-0330185	30-08-89	JP-A- 2023897	26-01-90
EP-A-0343955	29-11-89	None	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	WO,A,8 602 666 (MICROGENICS CORP.) 9 May 1986 cited in the application see the whole document ---	1-26
A	EP,A,0 309 230 (M.L. TECHNOLOGY VENTURES) 29 March 1989 cited in the application ---	
A	EP,A,0 330 185 (PROFILE DIAGNOSTIC SCIENCE) 30 August 1989 ---	
A	EP,A,0 343 955 (BIOVENTURES INC.) 29 November 1989 -----	